XML 49 R36.htm IDEA: XBRL DOCUMENT
v3.20.2

Segments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Summary of Segment Profit |
a. | Segment information:
|  | Three months ended September 30, |
|  | 2020 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,017 |  |  | $ | 1,116 |  |  | $ | 529 |
Gross profit |  |  | 1,056 |  |  |  | 637 |  |  |  | 275 |
R&D expenses |  |  | 155 |  |  |  | 60 |  |  |  | 17 |
S&M expenses |  |  | 250 |  |  |  | 200 |  |  |  | 101 |
G&A expenses |  |  | 97 |  |  |  | 66 |  |  |  | 33 |
Other income |  |  | (5 | ) |  |  | (1 | ) |  |  | (1 | )
Segment profit |  | $ | 560 |  |  | $ | 312 |  |  | $ | 125 |
|  | Three months ended September 30, |
|  | 2019 |
|  | North America |  |  | Europe |  |  | International Markets* |
|  | (U.S. $ in millions) |
Revenues |  | $ | 2,051 |  |  | $ | 1,163 |  |  | $ | 565 |
Gross profit |  |  | 1,048 |  |  |  | 662 |  |  |  | 295 |
R&D expenses |  |  | 156 |  |  |  | 63 |  |  |  | 21 |
S&M expenses |  |  | 219 |  |  |  | 206 |  |  |  | 114 |
G&A expenses |  |  | 112 |  |  |  | 56 |  |  |  | 32 |
Other (income) expense |  |  | (5 | ) |  |  | (4 | ) |  |  | (1 | )
Segment profit |  | $ | 565 |  |  | $ | 341 |  |  | $ | 130 |
|  | Nine months ended September 30, |
|  | 2020 |
|  | North America |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 6,146 |  |  | $ | 3,520 |  |  | $ | 1,582 |
Gross profit |  |  | 3,208 |  |  |  | 2,009 |  |  |  | 828 |
R&D expenses |  |  | 455 |  |  |  | 180 |  |  |  | 51 |
S&M expenses |  |  | 755 |  |  |  | 590 |  |  |  | 312 |
G&A expenses |  |  | 325 |  |  |  | 184 |  |  |  | 96 |
Other income |  |  | (9 | ) |  |  | (3 | ) |  |  | (10 | )
Segment profit |  | $ | 1,682 |  |  | $ | 1,058 |  |  | $ | 378 |
|  | Nine months ended September 30, |
|  | 2019 |
|  | North America |  |  | Europe |  |  | International Markets* |
|  | (U.S. $ in millions) |
Revenues |  | $ | 6,169 |  |  | $ | 3,611 |  |  | $ | 1,668 |
Gross profit |  |  | 3,155 |  |  |  | 2,066 |  |  |  | 877 |
R&D expenses |  |  | 497 |  |  |  | 199 |  |  |  | 66 |
S&M expenses |  |  | 756 |  |  |  | 637 |  |  |  | 348 |
G&A expenses |  |  | 342 |  |  |  | 175 |  |  |  | 102 |
Other income |  |  | (6 | ) |  |  | (5 | ) |  |  | (2 | )
Segment profit |  | $ | 1,566 |  |  | $ | 1,060 |  |  | $ | 363 |
* | The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c.
Schedule Of Consolidated Income Before Income Tax | The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended September 30, 2020 and 2019:
|  | Three months ended |  |  | Nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |  |  | (U.S. $ in millions) |
North America profit |  | $ | 560 |  |  | $ | 565 |  |  | $ | 1,682 |  |  | $ | 1,566 |
Europe profit |  |  | 312 |  |  |  | 341 |  |  |  | 1,058 |  |  |  | 1,060 |
International Markets profit |  |  | 125 |  |  |  | 130 |  |  |  | 378 |  |  |  | 363 |
Total reportable segments profit |  |  | 997 |  |  |  | 1,036 |  |  |  | 3,118 |  |  |  | 2,989 |
Profit of other activities |  |  | 28 |  |  |  | 16 |  |  |  | 130 |  |  |  | 92 |
Total segments profit |  |  | 1,025 |  |  |  | 1,051 |  |  |  | 3,248 |  |  |  | 3,081 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization |  |  | 251 |  |  |  | 255 |  |  |  | 758 |  |  |  | 823 |
Other assets impairments, restructuring and other items |  |  | (98 | ) |  |  | 160 |  |  |  | 404 |  |  |  | 263 |
Intangible asset impairments |  |  | 509 |  |  |  | 177 |  |  |  | 1,278 |  |  |  | 1,206 |
Goodwill impairment |  |  | 4,628 |  |  |  | — |  |  |  | 4,628 |  |  |  | — |
Legal settlements and loss contingencies |  |  | 21 |  |  |  | 468 |  |  |  | 10 |  |  |  | 1,171 |
Other unallocated amounts |  |  | 55 |  |  |  | 73 |  |  |  | 148 |  |  |  | 209 |
Consolidated operating income (loss) |  |  | (4,342 | ) |  |  | (81 | ) |  |  | (3,978 | ) |  |  | (591 | )
Financial expenses, net |  |  | 117 |  |  |  | 211 |  |  |  | 565 |  |  |  | 635 |
Consolidated income (loss) before income taxe s |  | $ | (4,459 | ) |  | $ | (292 | ) |  | $ | (4,543 | ) |  | $ | (1,226 | )
Schedule of Net Sales by Product Line | The following tables present revenues by major products and activities for the three and nine months ended September 30, 2020 and 2019:
North America |  | Three months ended September 30, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 928 |  |  | $ | 914 |
AJOVY |  |  | 35 |  |  |  | 25 |
AUSTEDO |  |  | 168 |  |  |  | 105 |
BENDEKA ® /TREANDA ® |  |  | 105 |  |  |  | 124 |
COPAXONE |  |  | 236 |  |  |  | 271 |
ProAir ® * |  |  | 50 |  |  |  | 71 |
QVAR ® |  |  | 42 |  |  |  | 60 |
Anda |  |  | 341 |  |  |  | 351 |
Other |  |  | 113 |  |  |  | 131 |
Total |  | $ | 2,017 |  |  | $ | 2,051 |
* | Does not include revenues from the ProAir authorized generic, which are included under generic products.
North America |  | Nine months ended September 30, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 2,804 |  |  | $ | 2,826 |
AJOVY |  |  | 98 |  |  |  | 68 |
AUSTEDO |  |  | 451 |  |  |  | 276 |
BENDEKA/TREANDA |  |  | 313 |  |  |  | 371 |
COPAXONE |  |  | 671 |  |  |  | 753 |
ProAir* |  |  | 175 |  |  |  | 194 |
QVAR |  |  | 139 |  |  |  | 183 |
Anda |  |  | 1,141 |  |  |  | 1,080 |
Other |  |  | 354 |  |  |  | 417 |
Total |  | $ | 6,146 |  |  | $ | 6,169 |
* | Does not include revenues from the ProAir authorized generic, which are included under generic products.
Europe |  | Three months ended September 30, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 824 |  |  | $ | 836 |
COPAXONE |  |  | 101 |  |  |  | 106 |
Respiratory products |  |  | 77 |  |  |  | 87 |
AJOVY |  |  | 8 |  |  |  | 1 |
Other |  |  | 106 |  |  |  | 134 |
Total |  | $ | 1,116 |  |  | $ | 1,163 |
Europe |  | Nine months ended September 30, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 2,593 |  |  | $ | 2,599 |
COPAXONE |  |  | 294 |  |  |  | 327 |
Respiratory products |  |  | 263 |  |  |  | 267 |
AJOVY |  |  | 17 |  |  |  | 1 |
Other |  |  | 352 |  |  |  | 416 |
Total |  | $ | 3,520 |  |  | $ | 3,611 |
International Markets |  | Three months ended September 30, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 429 |  |  | $ | 474 |
COPAXONE |  |  | 14 |  |  |  | 20 |
Other |  |  | 86 |  |  |  | 71 |
Total |  | $ | 529 |  |  | $ | 565 |
* | The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c.
International Markets |  | Nine months ended September 30, |
|  | 2020 |  |  | 2019 |
|  | (U.S. $ in millions) |
Generic products |  | $ | 1,304 |  |  | $ | 1,404 |
COPAXONE |  |  | 38 |  |  |  | 46 |
Other |  |  | 241 |  |  |  | 218 |
Total |  | $ | 1,582 |  |  | $ | 1,668 |
* | The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1c.

X
- Definition Schedule of consolidated income before income tax. + References No definition available. + Details
Name: | teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration